These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
    Author: Sato K.
    Journal: Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477.
    Abstract:
    Immunosuppressive treatments, such as rituximab-containing chemotherapy or stem cell transplantation, have been widely performed following recent developments in cancer therapy. Immunosuppressive therapy or chemotherapy(IS/CT)-induced reactivation of the hepatitis B virus(HBV)in HBsAg-positive HBV-carriers is a well-known phenomenon. It has recently been demonstrated that HBV-reactivation also occurs in HBV-resolved patients who are negative for HBsAg, and positive for HBsAb and/or HBcAb. This is because de novo hepatitis B, which occurs in HBV-resolved patients with a recurrence of HBV hepatitis, have a high risk of fulminant hepatitis with an extremely poor prognosis. In this regard, prevention a guideline for IS/ CT-induced HBV-reactivation was established in Japan. However, the incidence of, and risk factors for, IS/CT-induced HBV- reactivation in HBV-resolved patients in Japan has not yet been elucidated. We retrospectively analyzed IS/CT-induced HBV- reactivation in resolved HBV-patients with hematological disorders in our hospital. Reactivation occurred in 5. 0%patients(5/ 101), and administration of more than 2 regimens for the hematological disorder was identified as an independent risk factor for HBV-reactivation in multivariate analysis. Further investigation of the risk factors for HBV-reactivation and the efficacy of the guideline should be performed during multicenter prospective study.
    [Abstract] [Full Text] [Related] [New Search]